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Nox2 is a ROS-generating enzyme, deficiency of which increases suppression by Tregs 310	
in vitro and in an in vivo model of cardiac remodelling. Since Tregs have emerged as a 311	
candidate therapy in autoimmunity and transplantation, we hypothesised that Nox2 312	
deficiency in Tregs in recipient mice may improve outcomes in a heart transplant model. 313	
A novel B6129 mouse model with Treg-targeted Nox2 deletion (Nox2fl/flFoxP3Cre+) was 314	
generated and transplanted with hearts from CB6F1 donors. As compared to littermate 315	
controls, Nox2fl/flFoxP3Cre+ mice had lower plasma levels of alloantibodies and 316	
troponin-I, reduced levels of IFN-g in heart allograft homogenates and diminished 317	
cardiomyocyte necrosis and allograft fibrosis. Single cell analyses of allografts revealed 318	
higher absolute numbers of Tregs and lower CD8+ T cell infiltration in Nox2-deficient 319	
recipients compared to Nox2-replete mice. Mechanistically, in addition to a greater 320	
suppression of CD8+CD25- T effector cell proliferation and IFN-g production, Nox2-321	
deficient Tregs expressed higher levels of CCR4 and CCR8, driving cell migration to 322	
allografts; this was associated with increased expression of miR214-3p. These data 323	
indicate that Nox2 deletion in Tregs enhances their suppressive ability and migration to 324	
heart allografts. Therefore, Nox2 inhibition in Tregs may be a useful approach to 325	
improve their therapeutic efficacy. 326	











Cardiac transplantation remains the only available “curative” therapy for end-stage heart 337	
failure. However, the average survival after surgery is less than 10 years due to immune-338	
mediated allograft rejection and side effects of immunosuppressive drugs (1). This 339	
provides the impetus to manipulate the immune system to achieve heart allograft 340	
tolerance (2).  341	
Tregs are a subset of T cells expressing the transcription factor FoxP3 and the 342	
surface molecules CD4 and CD25 (3). In addition to maintaining self-tolerance (4), Tregs 343	
can recognize allogeneic MHC molecules and inhibit allograft rejection through different 344	
mechanisms (5). Tregs are currently under intensive investigation as an adoptive cell-345	
based therapy to prevent transplant rejection and treat autoimmune diseases (6). 346	
Polyclonal Treg-based cell therapy approaches yielded promising early results for the 347	
prevention of graft-versus-host disease (GvHD) (7), and for the cure of type I diabetes 348	
(8, 9). We have also completed two Phase I/II clinical trials, the ONE Study 349	
(NCT02129881) (10) and ThRIL (NCT02166177) (11), assessing the safety and 350	
feasibility of adoptive transfer of ex vivo expanded polyclonal Tregs in renal and liver 351	
transplant patients (12-14). 352	
Manipulation of Tregs in vitro can enhance their beneficial therapeutic effect (15, 353	
16). Recently, our group showed that murine Nox2-deficient Tregs have higher 354	
suppressive activity in vitro on CD4+ T effector cell (Teff) proliferation than WT Tregs, 355	
which was attributed to increased nuclear levels of FoxP3 and NF-κB, which led to 356	
increased expression of CD25, CTLA-4, CD39 and CD73, key molecules linked to Treg 357	
suppressive function (17). An increased potency of Nox2-deficient Tregs was also 358	
manifest in vivo by reducing inflammation in a model of angiotensin II-(ANGII)-induced 359	
cardiovascular remodelling.  360	
Having shown that Nox2 impairs Treg suppressive function, we hypothesized that 361	
targeting its deletion in FoxP3+ T cells of recipient mice could improve heart allograft 362	
survival.   363	
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Results  364	
Generation of mice with Nox2 deletion in Tregs 365	
To analyse the contribution of Nox2 in Tregs to allograft protection, mice with FoxP3-366	
targeted Nox2 deletion (Nox2fl/flFoxP3Cre+) were generated by crossing male B6129S-367	
Tg(FoxP3eGFP/iCre)1aJbS/J (18) with female Nox2fl/fl mice(19) (Supplementary Figure 368	
1A). Nox2fl/flFoxP3Cre+ mice were confirmed to have Nox2 DNA recombination 369	
(Supplementary Figure 1B) and the EGFP+ cells in Nox2fl/flFoxP3Cre+ were 95% 370	
CD25+FoxP3+ (Figure 1A). Nox2fl/flFoxP3Cre+ mice also had lower Nox2 mRNA levels 371	
(Figure 1B) in lymph nodes and reduced Nox2 protein levels in CD4+FoxP3+ but not 372	
CD4+FoxP3- cells (Figure 1C-D). Purified Tregs from Nox2fl/flFoxP3Cre+ mice did not 373	
increase ROS production after stimulation with anti-CD3ε and anti-CD28 Abs unlike cells 374	
from control Nox2fl/fl mice. In fact, after stimulation, Tregs from Nox2fl/flFoxP3Cre+ mice 375	
produced comparable ROS levels to Tregs from littermate controls treated with a Nox2 376	
flavoprotein inhibitor, diphenyleneiodonium (DPI; Figure 1E-F).   377	
 Under baseline conditions, Nox2fl/fl control and Nox2fl/flFoxP3Cre+ mice had 378	
similar numbers of CD4+ and CD8+ cells in thymus, spleen and mesenteric lymph nodes 379	
(Supplementary Figure 2A-C), including naïve (CD44-CD62L+), memory 380	
(CD44+CD62L+), Th17 (CD4+RORγT+), CD4+Tregs (CD25+FoxP3+ cells), CD8+Tregs 381	
(CD8+FoxP3+ cells) and CD4+CD8+ T cells (in thymus only). Nox2fl/flFoxP3Cre+ and 382	
control Nox2fl/fl mice had similar baseline heart and vascular function parameters 383	
(Supplementary Figure 2D-F).  384	
 385	
Nox2 deficiency in Tregs improves allograft outcome 386	
Mice with FoxP3-targeted Nox2 deletion (Nox2fl/flFoxP3Cre+; H-2b) and littermate 387	
controls (Nox2fl/fl; H-2b) were transplanted with hearts from CB6F1 mice (H-2b/d). 388	
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Allografts transplanted into Nox2fl/flFoxP3Cre+ mice showed delayed rejection as 389	
compared to those into littermate controls (Figure 2A, Supplementary video 1 and 2), 390	
along with diminished cardiomyocyte necrosis (Supplementary Figure 3A) and 391	
myocardial fibrosis (Supplementary Figure 3B) 7 and 100 days after surgery. To further 392	
confirm the relevance of Nox2 deletion in Tregs to the protection from heart allograft 393	
rejection, an animal model that more closely resembles the clinical setting was used. 394	
Recipient mice were treated with cyclosporin (30mg/kg) for 10 days after heart 395	
transplantation. Both Nox2fl/fl and Nox2fl/flFoxP3Cre+ mice had increased allograft survival 396	
rates after cyclosporin treatment, but the Nox2fl/flFoxP3Cre+ mice showed a lower rate of 397	
rejection (Figure 2A). 398	
Plasma troponin-I levels were lower in Nox2fl/flFoxP3Cre+ mice compared to 399	
littermate controls (Figure 2B) 7 days after transplantation. Plasma alloantibody levels 400	
were reduced in mice with Treg-targeted Nox2-deficiency 7 and 100 days after 401	
transplantation (Figure 2C-D), whilst the inflammatory mediators CCL2, IL-10 and IL-6 402	
in allograft homogenates (Supplementary Figure 3C-E) and CCL1 and CCL22 mRNA 403	
levels in heart tissues (Supplementary Figure 3F-G) were equivalent between the two 404	
groups of mice 7 days after surgery. 405	
To evaluate the contribution of Tregs to improved heart allograft outcome, the 406	
presence of FoxP3+GFP+ cells was first analysed in hearts transplanted into B6129S-407	
Tg(FoxP3eGFP/iCre)1aJbS/J mice. The number of recipient-FoxP3+GFP+ Tregs in 408	
allografts started increasing 3 days after transplant, peaked at day 7 and then decreased 409	
by day 14 (Figure 2E). The increased number of Tregs at day 7 coincided with the higher 410	
FoxP3+ Treg numbers and Treg/Teff ratios observed in allografts transplanted in 411	
Nox2fl/flFoxP3Cre+ mice compared to controls Nox2fl/fl (Figure 2F-H). The higher Treg 412	
number was associated with reduced CD8+ cells but not CD4+ T cells in the allografts 413	
(Figure 2I-J). Moreover, Nox2fl/flFoxP3Cre+ mice had lower IFN-g levels in heart 414	
homogenates than Nox2fl/fl 7 days after transplantation (Figure 2K). The numbers of 415	
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CD4+, CD8+ and FoxP3+ Tregs in spleen were similar between Nox2fl/flFoxP3Cre+ and 416	
Nox2fl/fl mice (Supplementary Figure 4). 417	
Therefore, Nox2 deficiency in Tregs improves heart transplant outcomes and 418	
prevents acute rejection through the reduction of CD8+ cell infiltration and IFN-g 419	
production in the allografts associated with a higher proportion of Tregs.  420	
 421	
Nox2-deficient Tregs exhibit higher suppression of CD8+ T cell proliferation 422	
 We have previously shown that Nox2-deficient Tregs inhibit in vitro CD4+ T Teff 423	
proliferation more efficiently than WT Tregs (17). To assess whether the reduced number 424	
of CD8+ T cells in the transplanted hearts in Nox2fl/flFoxP3Cre+ recipient mice was due 425	
to a superior inhibitory function of Nox2-deficient Tregs, we purified and co-cultured 426	
CD4+CD25+ Tregs with CD8+CD25- Teffs. Tregs deficient in Nox2 inhibited CD8+ WT 427	
Teff proliferation (Supplementary Figure 5A-B) more efficiently than WT Tregs (IC50 0.13 428	
vs IC50 0.41). Additionally, Nox-2-deficient Tregs abolished the production of IFN-g by 429	
CD8+ T effs whereas a dose-dependent decrease was observed using different ratios of 430	
WT Tregs: WT Teffs (Supplementary Figure 5C). 431	
Therefore, Nox2-/- Tregs exhibit higher suppression of CD8+ Teff proliferation and 432	
IFN-γ production than WT Tregs.  433	
 434	
Nox2 deficiency favours Treg migration and homing into heart allografts  435	
A potential mechanism underlying the increased number of recipient-Tregs in 436	
allografts is augmented leukocyte trafficking. Chemokine receptors are essential for the 437	
initial phases of leukocyte trafficking (20) and were first analysed in WT and Nox2-438	
deficient Tregs purified from spleen and lymph nodes. These cells were predominantly 439	
thymus-derived Tregs, as approximately 70% of them were neurophilin-1+ 440	
(Supplementary Figure 6). Of the 17 chemokine receptors evaluated, six had enhanced 441	
	 15	
mRNA levels in Nox2-deficient Tregs (Figure 3A). Among these, CCR4 is of particular 442	
interest as it has been described as a homing receptor for the heart (21). The protein 443	
levels of CCR2, CCR4, CCR6, CCR7, CCR8 and CXCR4 were further investigated by 444	
multi-colour flow cytometry (Figure 3B-C and Supplementary Figure 7A-B). Nox2-445	
deficient Tregs showed higher CCR4 and CCR8 expression than WT Tregs (Figure 3B-446	
C), along with a higher chemotactic index toward CCL22 and CCL1, respectively (Figure 447	
3D). The difference in chemotaxis was abolished by pre-incubation of Tregs with 448	
Ly294002, an inhibitor of phosphoinositide 3-kinases - a known downstream effector of 449	
chemokine receptor signalling (22). Nox2-deficient Tregs also showed higher F-actin 450	
assembly following incubation with CCL1 and CCL22 (Figure 3E-F). Of note, CCR2, 451	
CCR4, CCR7, CCR8 and CXCR4 protein levels in CD4+CD25-FoxP3- and CD8+CD25-452	
FoxP3- Teffs were comparable between WT and Nox2-deficient mice (Supplementary 453	
Figure 7C-D). To further confirm the superior migratory capacity of Nox2-deficient Tregs 454	
in vivo, WT and Nox2-deficient Tregs (H-2b), stained in green and orange respectively, 455	
were adoptively co-transferred into B6 mice transplanted with CB6F1 hearts (Figure 3G). 456	
Supporting the previous results, a greater number of Nox2-deficient Tregs were 457	
recovered from the allografts as compared to WT Tregs (Figure 3H).  458	
Chemokines mediate integrin activation via inside-out signalling and 459	
consequently induce adhesion of lymphocytes to ECs (23). Therefore, in addition to 460	
chemotaxis, an increase in numbers of Tregs in the allograft may also be influenced by 461	
their adherence to cardiac ECs. After stimulation with CCL22, Tregs deficient in Nox2 462	
displayed higher binding in vitro to ICAM-1 than WT Tregs (Figure 3I-J). Moreover, when 463	
WT and Nox2-deficient Tregs stained in contrasting colour dyes were co-perfused over 464	
cardiac ECs, the Nox2-deficient cells displayed higher adherence to ECs (Figure 3K).  465	
Taken together, our data suggest that Nox2 expression in Tregs negatively 466	
regulates their chemotaxis and EC adherence. 467	
 468	
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miR-214-3p drives increased CCR4 and CCR8 expression in Nox2-deficient Tregs 469	
The intracellular mechanism by which Nox2 controls transcription of CCR4 and 470	
CCR8 in T cells was next investigated. Because miRNAs are important regulators of 471	
transcription and a previous study showed that miR-214 deficiency decreases CCR4 472	
expression in T cells (24), we assessed this as a possible mechanism. PCR analyses 473	
using primers for these miRs revealed that Nox2-deficient Tregs have higher expression 474	
of miR-214-3p but comparable levels of miR-214-5p to WT Tregs (Figure 4A, 475	
Supplementary Figure 8A). Accordingly, Jurkat T cells incubated with a specific Nox2 476	
inhibitor, gp91ds-tat, had higher mRNA levels of CCR4 and CCR8 than those incubated 477	
with sc-tat peptide control. This increase was prevented in cells transfected with a miR-478	
214-3p inhibitor (Figure 4B-C). Transfection of Jurkat T cells with miR-214-3p mimetic 479	
also increased CCR4 and CCR8 mRNA levels (Figure 4B-C) and cells treated with the 480	
Nox2 inhibitor showed higher miR 214-3p levels, which was reduced by transfection 481	
with the miR inhibitor (Supplementary Figure 8B). The incubation of Jurkat T cells with 482	
PEG-SOD and PEG-catalase also increased the levels of miR-214-3p as well as CCR4 483	
and CCR8 mRNAs, indicating that the Nox2 effects were ROS-dependent (Figure 4D-484	
F). We next cloned the 3’ untranslated region (UTR) of mouse CCR4 and part of the 485	
coding region harbouring binding sites for miR-214-3p in CCR4 and CCR8 mRNAs into 486	
a dual-luciferase reporter vector. Jurkat T cells transfected with the CCR4 constructs 487	
showed a higher luciferase signal in the presence of gp91ds-tat or the miR-214-3p 488	
mimetic (Figure 4G-H), suggesting increased CCR4 mRNA stabilization. The assays 489	
using the CCR8 construct showed an increased signal in the presence of gp91ds-tat 490	
but not miR-214-3p mimetic, pointing to a possible distinct regulatory mechanism 491	
(Figure 4I).  492	
Finally, we studied the expression of mRNA for Nox2, FoxP3 and miR214-3p in 493	
heart allografts, 7 days after transplantation. The expression of mRNA for FoxP3 in the 494	
allografts directly correlated with the Treg counts (Figure 5A), and inversely correlated 495	
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with the expression of mRNA for Nox2 (Figure 5B). In agreement with the results 496	
presented in figures 2F-G and 4A, Nox2 mRNA expression inversely correlated with 497	
Treg cell counts and with miR214-3p expression in the heart allografts (Figure 5C-D).  498	
Taken together, our results indicate that Nox2 deficiency in Tregs improves heart 499	
allograft outcomes due to a greater suppression of CD8+ Teff proliferation and IFN-g 500	
production. Additionally, Nox2-deficient Treg migrate more efficiently into the allografts 501	
due to their increased expression of CCR4 and CCR8 mRNAs mediated via miR214-3p. 502	
 503	
Discussion 504	
The development of improved methods to suppress cardiac transplant rejection is a 505	
major goal to enhance the effectiveness of this life-saving therapy. Previous work, 506	
including early-phase clinical studies, suggests that the administration of Tregs may be 507	
one way to induce immune tolerance and improve allograft outcome (7, 11). We focused 508	
on the ROS-generating enzyme Nox2, as we have recently found it to reduce Treg 509	
suppression of CD4+ Teff proliferation (17) and thereby increase cardiovascular 510	
inflammatory responses. Here, a novel mouse model with Treg-specific deficiency of 511	
Nox2 in the recipient showed improved allograft outcomes, which were accompanied by 512	
reduced cardiomyocyte necrosis, lower myocardial fibrosis and diminished circulating 513	
levels of alloantibodies. The mechanisms underlying these improved outcomes were 514	
increased chemotaxis and adherence of Tregs in the transplanted hearts as well as an 515	
enhanced suppression of CD8+CD25- Teff proliferation by Nox2 deficient CD4+CD25+ 516	
cells. Additionally, Nox2-deficient Tregs downregulated IFN-g production in cultures with 517	
CD8+ Teff cells, which could also have contributed to increase survival of the heart 518	
allografts.  519	
Nox2 was previously shown to be involved in leukocyte migration in distinct 520	
disease contexts and related to different cell types, including ECs (25), platelets (26) and 521	
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neutrophils (27). In the present study, we observed that Nox2 deficiency upregulates 522	
CCR4 expression in CD4+CD25+ Tregs, which favours their infiltration into heart 523	
allografts. The importance of Treg chemotaxis toward CCR4 ligands in the context of 524	
heart allograft survival is corroborated by previous studies (28-30). Long term allograft 525	
survival induced by treatment with tanshinol plus rapamycin was reversed by neutralizing 526	
the CCR4 ligand CCL22 (29). Furthermore, Lee et al. (28) showed that upregulation of 527	
CCR4 and Treg infiltration of the transplant following combined anti-CD154 monoclonal 528	
antibody and donor-specific transfusion induced tolerance, which was not observed in 529	
CCR4-deficient recipients nor in mice receiving anti-CD25 antibody treatment.  530	
It is well known that CCR4 inside-out signaling activates the integrin CD11a, 531	
which adheres more to ICAM-1 expressed by antigen-presenting cells (APCs) and ECs 532	
(31, 32). In fact, we observed that Nox2-deficient Tregs had enhanced binding to ICAM-533	
1 in vitro after CCL22 stimulation as compared to WT Tregs. As a consequence, Tregs 534	
deficient of Nox2 had a higher adherence to cardiac ECs, facilitating migration into 535	
allografts; the possible increased interaction with APCs, reducing their capacity to 536	
provide costimulatory signals, could have contributed to a higher suppression of 537	
CD8+Teff proliferation. Corroborating the importance of integrin activation to heart 538	
allograft survival, Warren et al.(32), showed that anti-α4 integrin antibody reduced the 539	
number of Tregs in transplanted hearts leading to impaired allograft survival. The 540	
increased CCR8 expression displayed by Nox2-deficient Tregs could also have 541	
contributed to enhanced chemotaxis to allografts and to the higher suppressive function. 542	
In support of this, Barsheshet et al.(33) showed that the suppressive function of 543	
CD25+CD127lo Tregs in vitro is upregulated by expression of CCR8 and the presence of 544	
its ligand CCL1 (33). Nox2-deficient Tregs showed enhanced expression of mRNA for 545	
six different chemokine receptors despite only CCR4 and CCR8 having corresponding 546	
increases in protein levels as compared to WT Tregs. These discrepancies could be due 547	
to internalization and degradation of chemokine receptors (22).  548	
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We further explored the intracellular mechanism through which Nox2 regulates 549	
CCR4 and CCR8 expression in T cells and found that miR-214-3p is enhanced in Nox2-550	
deficient Tregs. Our data support an miR-dependent upregulation of target mRNA 551	
transcription or stabilization previously reported in the literature (34-36). Consistently, 552	
hearts from miR-214-deficient mice displayed lower CCR4 expression compared to WT 553	
controls (24), indicating upregulation rather than reduction of mRNA levels. Additionally, 554	
Nox2 mRNA levels in heart allografts inversely correlated to miR-214-3p levels, Treg 555	
counts and FoxP3 mRNA expression. Our results agree with a previous study showing 556	
an association between decreased expression of miR214-3p and increased levels of 557	
alloantibodies and development of bronchiolitis obliterans syndrome following lung 558	
transplantation (37). Additionally, murine heart allografts had lower levels of miR214-3p 559	
compared to isografts (38). 560	
The higher Treg infiltration in recipient mice with Treg-targeted Nox2 deletion was 561	
associated with lower necrosis and fibrosis of heart allografts and with lower plasma 562	
levels of troponin-I as early as 7 days after surgery. Indeed, increased troponin-I levels 563	
correlated positively in patients with acute heart transplant rejection (39), which was also 564	
observed in the murine heterotopic heart transplant model used in this study.   565	
The lower interstitial fibrosis observed in allografts transplanted into recipient 566	
mice with Nox2 deletion agrees with our recent published data showing that the adoptive 567	
transfer of Nox2-deficient Tregs induced lower cardiac fibrosis in a model of ANGII- 568	
induced cardiovascular remodelling (17). It also agrees with another study showing Treg 569	
depletion using anti-CD25 antibody aggravated cardiac fibrosis in a model of virus-570	
induced myocarditis whereas adoptive transfer of Tregs prevented it (40). 571	
In addition to impaired T cell mediated alloresponses, there was a significant 572	
decrease in levels of alloantibodies in mice with Nox2-deficiency in Tregs as compared 573	
to controls with preserved Nox2 activity. Since post-transplantation reactive anti-HLA 574	
antibodies in humans are associated with the development, frequency and severity of 575	
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cardiac allograft vasculopathy (CAV), it would be of interest to assess whether Nox2 576	
deficiency in Tregs also impacts on this serious complication after heart transplantation 577	
(41). 578	
We did not see differences in CD4+ T cell infiltration between allografts 579	
transplanted into Nox2fl/fl and Nox2fl/flFoxP3Cre+mice. This response differs from the 580	
pattern of T cell infiltration in a model of ANGII-induced cardiac remodelling, in which 581	
Nox2-deficient mice had a decrease in both CD4+ and CD8+ T effector cells (17). These 582	
differences could be attributed to the distinct importance of CD4+ and CD8+ cells in 583	
different animal models. In fact, cytotoxic CD8+ T-cell responses against mismatched 584	
MHC Class I alloantigen are the principal arm of the cellular response against the 585	
transplanted organ (42) whereas cardiac remodelling is modulated mainly by CD4+ T 586	
cells producing IL-17 (43). 587	
Nox2-deficient Tregs express higher levels of CCR4 and CCR8, but other 588	
chemokine receptors were not affected (CCR2, CCR7, CCR6 and CXCR4- 589	
Supplementary Figure 7A-B). Therefore, the presence of CCL1 and CCL22 in the heart 590	
transplant microenvironment increases the potential therapeutic effects of Nox2-deficient 591	
Tregs in this context. Because Nox2-deletion does not reduce the expression of other 592	
chemokine receptors, other disease-contexts where CCL1 and CCL22 have a secondary 593	
role probably would not be negatively affected by Nox2-deletion in Tregs. 594	
In conclusion, we observed that Nox2-deficiency increased the suppressive 595	
capacity and chemotaxis of Tregs in vitro and in vivo. Therefore, Nox2 could be used as 596	





Material and methods 601	
  602	
Mice and in vivo studies. Nox2fl/flFoxP3Cre+ mice were generated by crossing B6129S-603	
Tg (FoxP3-EGFP/iCre)1aJbs males with Nox2 homozygous floxed females(19). 604	
Heterotopic heart transplants were performed as previously described (44).  605	
 606	
ELISA. Troponin-I and IFN-γ levels were determined by ELISA according to 607	
manufacturer’s recommendations. 608	
 609	
Treg purification. CD4+CD25+ cells were purified from spleen and lymph nodes using a 610	
commercial kit (DynabeadsTM FlowCompTM Mouse CD4+CD25+ Treg, Cat. 11463D). 611	
 612	
Flow cytometry. Levels of alloantibodies in plasma and single cell analyses of heart 613	
allograft digests were determined in a LSRFORTESSA flow cytometer (BD Biosciences, 614	
Oxford, UK) and analysed using FlowJo software 9.7.5 (Ashland, USA). Superoxide 615	
production was estimated using 10 μM dihydroethidium(17). 616	
 617	
Quantitative PCR. RNA was extracted using TrizolTM Reagent. SYBR green real-time 618	
PCR was performed using the DDCt method and GAPDH for normalization. cDNA 619	
synthesis and q-PCR for miR-214-3p and miR-214-5p were done using an miCury 620	
LNAtm MiRNA PCR starter kit, mmu-miR-214-3p and mmu-miR-214-5p. 621	
 622	
Cell transfection. Jurkat T cells were transfected with microRNA mimic miR-214-3p or 623	
hsa-miR-214-3p miRCURY LNA miRNA Inhibitor or miRVanatm miR mimic negative 624	
control by electroporation.  625	
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 626	
Statistics. Analyses were performed using GraphPad Prism software v9.0. Comparisons 627	
were undertaken using Kruskal-Wallis followed by Dunn’s post-test or a Mann Whitney 628	
t-test two tailed or 2-way ANOVA followed by Bonferroni post-test, as appropriate. A 629	
Mantel-Cox test was used to compare survival rates. P<0.05 was considered significant.  630	
 631	
Study approval. All animal procedures were undertaken in accordance with the Guidance 632	
on the Operation of the Animals (Scientific Procedures) Act, 1986 (UK Home Office) and 633	
institutional ethics approval from King’s College London, London, United Kingdom. 634	
 635	
See Supplementary Methods for additional information. 636	
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Figure 1. Generation of mice with Treg-targeted Nox2 deletion. (A) EGFP+ cells from 881	
lymph nodes of Nox2fl/flFoxP3Cre+ mice stained with CD25 and FoxP3 Abs. Plots are 882	
representative of 3 Nox2fl/flFoxP3Cre+ and 3 Nox2fl/fl mice. (B) Nox2 mRNA levels in 883	
lymph nodes (n=3-6 per group). (C-D) Nox2 protein levels in CD4+FoxP3+ and 884	
CD4+FoxP3- cells, respectively (n=6 per group). (E-F) ROS estimated by 885	
dihydroethidium (DHE) fluorescence in purified Tregs stimulated with anti-CD3 (4 μg/ml) 886	
and anti-CD28 (8 μg/ml) Ab (n=4-7 per group). Panels in E show representative 887	
histograms and mean data is displayed in F. Dashed line in E represents the MFI of 888	
Nox2fl/fl cells pre-incubated with the flavoprotein inhibitor diphenyleneiodonium (DPI, 10 889	
μM) 30 minutes before stimuli. Data are shown as mean ±SEM; *P<0.05 for indicated 890	
comparisons; Mann Whitney t-test (two tailed) in B and C; Kruskal Wallis followed by 891	
Dunn’s post-test in D. 892	
	 30	
 893	
Figure 2. Heart allografts transplanted into Nox2fl/flFoxP3Cre+ mice have higher 894	
Treg infiltration and better outcome. Nox2fl/flFoxP3Cre+ mice and littermate controls 895	
(Nox2fl/fl) were transplanted with hearts from CB6F1 mice. Mice transplanted with hearts 896	
from B6 mice were used as isograft controls. (A) Allograft survival curves. Some mice 897	
were treated daily with cyclosporin (30 mg/kg) s.c., for 10 days after transplantation (n=4-898	
	 31	
5 per group). (B) Plasma troponin-I levels 7 days after transplant. (C- D) Plasma 899	
alloantibodies 7 and 100 days after the transplant. Representative histograms in D show 900	
the data obtained 100 days after transplant. (n=3- 5 per group).  (E) Representative plots 901	
of one experiment realized in triplet of allografts showing the infiltration of EGFP+ 902	
recipient Tregs (F-G) Representative plots of CD25+FoxP3+ cells within the CD4+ cell 903	
population (F) and cells/mg of heart allograft 7 days after transplant (G). (H) Treg/Teff 904	
ratios. (I-J) CD4+ and CD8+ cells into transplanted hearts. Representative plots are 905	
shown in I and cells/mg tissue in J. (K) IFN-γ levels in heart allograft homogenates 7 906	
days after surgery. Data are shown as mean ±SEM; *P<0.05 for indicated comparisons; 907	
Kruskal-Wallis followed by Dunn’s post-test (n= 3-5 per group). † or *P<0.05 compared 908	
to Nox2fl/fl mice, Mantel-Cox test (A). 909	
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 910	
Figure 3. Nox2-deficient Tregs (Nox2-/-) express higher levels of CCR4 and CCR8 911	
than WT Tregs driving migration into heart allografts. Tregs were purified from 912	
spleen and lymph nodes of Nox2-/- or WT mice and assessed for: (A) mRNA levels of 913	
	 33	
chemokine receptors (n=12); (B-C) CCR4 and CCR8 protein levels by flow cytometry 914	
(n=6); (D) chemotaxis in vitro toward CCL1 and CCL22; (E-F) actin polymerization 915	
stimulated by CCL1 and CCL22. Some cells were incubated with Ly294002 (5 μM). Full 916	
minus one (FMO) Ab was used as a negative control. Graphs and images represent one 917	
from 3 independent experiments. (Scale bar: 32µm) (G-H)) WT and Nox2-/- Tregs were 918	
stained with different colour cell tracers and tested for infiltration (after adoptive transfer) 919	
into CB6F1 hearts transplanted in B6 recipients (n=4) (G-H); or adherence on cardiac 920	
ECs (K). (I-J) In vitro activation and binding of ICAM-1 in Tregs. Histograms and mean 921	
data represent one from 2 independent experiments. Data are shown as mean ±SEM; 922	
*P<0.05 for indicated comparisons; Mann-Whitney t-test (two tailed) in C, H and K; 923	
Kruskal-Wallis followed by Dunn’s post- test in D and E; 2-way ANOVA followed by 924	
Bonferroni’s post -test in J. 925	
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 926	
Figure 4. miR-214-3p is up regulated in Nox2-/- Tregs and controls CCR4 and CCR8 927	
mRNA expression. (A) Expression of miR-214-3p in Nox2-/- or WT Tregs (n=6). (B-C) 928	
CCR4 and CCR8 mRNA expression in Jurkat T cells transfected with miR-214-3p 929	
mimetic or inhibitor. Some cells were treated with the Nox2 inhibitor gp91ds-tat (30 μM) 930	
for 24 hours. Control cells were transfected with miR-negative control and incubated with 931	
35	
sc-tat for 24 hours. Graphs represent 2 independent experiments. (D-F) Levels of miR-932	
214-3p, mRNA coding for CCR4 and CCR8 in Jurkat T cells incubated 24 hours with933	
PEG-SOD (20 IU/ml) and PEG-catalase (300 IU/ml). Graphs represent 3 independent 934	
experiments (G-I) Reporter assay using CCR4, CCR4 UTR and CCR8 constructs. 935	
Graphs represent 2 independent experiments. Data are shown as mean ±SEM; *P<0.05 936	
for indicated comparisons; Mann-Whitney t-test (two tailed) in A, D-F and H; Kruskal-937	
Wallis followed by Dunn’s post-test in B-C, G and I. 938	
939	
Figure 5. Nox2 expression inversely correlates with expression of FoxP3 and miR 940	
214-3p. (A-D) Linear correlations between FoxP3 mRNA, Nox2 mRNA and miR 214-3p941	
expressions and Treg counts in heart allografts (n=9), 7 days after transplantation. 942	
Values of cycle threshold (2-DCT) for miR214-3p were normalized by miR-let-103; Nox2 943	
36	
and FoxP3 were normalized by GAPDH. The R2 values are displayed on the top of each 944	
correlation. 945	
946	
947	
948	
949	
